Duloxetine vs. Active Comparator for the Treatment of Depression
|ClinicalTrials.gov Identifier: NCT00067912|
Recruitment Status : Completed
First Posted : September 3, 2003
Last Update Posted : May 21, 2007
How duloxetine compares to a medication currently available for the treatment of depression in the treatment of patients with major depressive disorder.
The safety of duloxetine and any side effects that might be associated with it.
|Condition or disease||Intervention/treatment||Phase|
|Depression||Drug: Duloxetine Hydrochloride Drug: Venlafaxine Extended Release||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||480 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Duloxetine Versus Venlafaxine Extended Release in the Treatment of Major Depressive Disorder|
|Study Start Date :||April 2003|
|Actual Study Completion Date :||March 2004|
- Linear measure of global benefit-risk assessment. Benefit is defined as remission at endpoint (HMAD17 total score less than or equal to 7, a virtually symptom-free state.
- HAMD17 Response Rates: Response is defined as a greater or equal to 50% reduction in HAMD17 total score from baseline to endpoint.
- HAMD17 Time to First Response: Time to first response is defined as the visit where a sustained greater than or equal to 30% reduction in the Maier subscale of the HAMD17.
- HAMD17 Remission Rates: Remission is defined as a HAMD17 total score of less than or equal to 7 at endpoint.
- Hamilton Anxiety Rating Scale (HAMA) that measures the presence and severity of anxiety. The 14-item version of this scale will be used to assess the severity of anxiety and its improvement during the course of therapy.
- Clinical Global Impressions of Severity (CGI-Severity) Scale to record the severity of illness at the time of assessment.
- Patient's Global Impressions of Improvement (PGI Improvement) Scale is a patient-rated instrument that measures the improvement of the patient's symptoms.
- HAMD17 Subscales to evaluate severity of psychic and somatic manifestations of anxiety, as well as agitation; evaluate dysfunction in mood, work, and sexual activity, as well as overall motor retardation; evaluate initial, middle and late insomnia.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00067912
|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.|
|Calgary, Alberta, Canada|
|Study Director:||Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)||Eli Lilly and Company|